| Literature DB >> 26675595 |
Brian S Snarr1, Stephen M Paridon1, Jack Rychik1, David J Goldberg1.
Abstract
The Fontan operation is the final step of palliation for patients with a functionally single ventricle. Since its introduction in the 1970s, the Fontan surgery has become part of a successful surgical strategy that has improved single ventricle mortality. In recent years, we have become more aware of the limitations and long-term consequences of the Fontan physiology. Pulmonary vascular resistance plays an important role in total cavopulmonary circulation, and has been identified as a potential therapeutic target to mitigate Fontan sequelae. In this review, we will discuss the results of different pulmonary vasodilator trials and the use of pulmonary vasodilators as a treatment strategy for Fontan patients.Entities:
Keywords: Congenital heart disease; Fontan procedure; physiology; pulmonary vasodilator
Mesh:
Substances:
Year: 2015 PMID: 26675595 DOI: 10.1017/S1047951115002309
Source DB: PubMed Journal: Cardiol Young ISSN: 1047-9511 Impact factor: 1.093